Abby Gallagher
Family · Grand Island, NENPI 1043652472
Payments from drug & device makers
Across 85 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$333
- GSK$219
- United Therapeutics Corporation$158
- Grifols USA, LLC$107
- Amgen$102
- Boehringer Ingelheim$81
- plus $524 from 16 others
What the payments were for
- Food & beverage$1,523100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $333 |
| GSK | 20 | $219 |
| United Therapeutics Corporation | 5 | $158 |
| Grifols USA, LLC | 6 | $107 |
| Amgen | 5 | $102 |
| Boehringer Ingelheim | 5 | $81 |
| Jazz Pharmaceuticals Inc. | 4 | $71 |
| Insmed, Inc. | 3 | $52 |
| Merck | 2 | $51 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Harmony Biosciences LLC | 3 | $42 |
| Verona Pharma, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Philips North America LLC | 1 | $31 |
| Pfizer | 1 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Pulmonx Corporation | 1 | $14 |
How this compares
$1,523 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $58,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,857 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,481 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,752 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,290 |
| Ventolin HfaAlbuterol Sulfate | 15 | $862 |
| Azithromycin | 48 | $207 |
| Famotidine | 16 | $206 |
| Doxycycline Hyclate | 14 | $138 |
| Prednisone | 34 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $219 | $65,647107 claims |
| AstraZenecaBreztri Aerosphere | $333 | $7,85711 claims |
| Boehringer IngelheimStiolto Respimat | $81 | $5,75212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.
Other family in Grand Island
- Mark HarveyGrand Island$4K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.